Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization

Bioinformatics

Volumn 25, Issue 8, 2009, Pages 1040-1047

  Prosperi, Mattia C F ^a,b   D'Autilia, Roberto ^b   Incardona, Francesca ^b   De Luca, Andrea ^b   Zazzi, Maurizio ^c   Ulivi, Giovanni ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC MODEL; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LONG TERM CARE; MOLECULAR EVOLUTION; NONHUMAN; PHENOTYPE; POISSON DISTRIBUTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STOCHASTIC MODEL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 64549129092     PISSN: 13674803     EISSN: 13674811     Source Type: Journal    
DOI: 10.1093/bioinformatics/btn568     Document Type: Article

References (37)

1. Anderson,J.P. et al. (2001) Substitution model of sequence evolution for the human immunodeficiency virus type 1 subtype B gp120 gene over the C2-V5 region. J. Mol. Evol., 53, 55-62.
2. Baker,J.E. (1987) Reducing bias and inefficiency in the selection algorithm. In Grefenstette, J.J. (ed.), Proceedings of the Second International Conference on Genetic Algorithms and their Application, Hillsdale, New Jersey, USA, Lawrence Erlbaum Associates, pp. 14-21.
3. Beerenwinkel,N. et al. (2003) Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res., 31 3850-3855.
4. Beerenwinkel,N. and Drton,M. (2007) A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data. Biostatistics, 8, 53-71.
5. Castiglione,F. et al. (2004) Mutation, fitness, viral diversity and predictive markers of disease progression in a computational model of HIV-1 infection. AIDS Res. Hum. Retrov., 20, 1316-1325.
6. Castiglione,F. and Bernaschi,M. (2006) HIV-1 strategies of immune evasion. Int. J. Mod. Phys. C, 16, 1869-1879.
7. Castiglione,F. et al. (2007) Optimization of HAART with genetic algorithms and agent-based models of HIV infection. Bioinformatics 23, 3350-3355.
8. Cleveland,W.S. (1981) LOWESS: A program for smoothing scatterplots by robust locally weighted regression. Am. Stat., 35, 54.
9. Deforche,K. et al. (2007) Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment. Bioinformatics, 24, 34-41.
10. De Luca,A. et al. (2003) The prognostic value to predict virological outcomes of 14 distinct systems used to interpret the results of genotypic HIV-1 drug resistance testing in untreated patients starting their first HAART. HIV Med., 4, 20.
11. Ding,A.A. and Wu,H. (1999) Population HIV-1 dynamics in vivo: Applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics, 55, 410-418.
12. Ding,A.A. and Wu,H. (2000) A comparison study on models and fitting procedures for biphasic viral dynamics in HIV-1 infected patients treated with antiviral therapies. Biometrics, 56, 293-300.
13. Fischl,M.A. et al. (2007) Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS, 21, 325-333.
14. Huang,Y. et al. (2003) Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math. Biosci., 184, 165-186.
15. Karlin,S. and McGregor,J. (1964) On some stochastic models in genetics. In Gurland,J. (ed.) Stochastic Problems in Medicine and Biology. University of Wisconsin Press, Madison, WI, pp. 245-271.
16. Kim,H. and Perelson,A.S. (2006) Viral and latent reservoir persistence in HIV-1 infected patients on therapy. PLoS Comput. Biol., 2 e135.
17. Kimura,M. (1983) The Neutral Theory of Molecular Evolution. Cambridge University Press, Cambridge, UK.
18. Landi,A. et al. (2008) Modelling and control of HIV dynamics. Comput. Methods Prog. Biomed., 89, 162-168.
19. Leitner,T. et al. (1997) Tempo and mode of nucleotide substitutions in gag and env gene fragments in human immunodeficiency virus type 1 populations with a known transmission history. J. Virol., 71, 4761-4770.
20. Mansky,L.M. and Temin,H.M. (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol., 69, 5087-5094.
21. Michalewicz,Z. (1994) Genetic algorithms + data structures = evolution programs. AI series, Springer-Verlag, NY.
22. Mocroft,A. et al. (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet, 352, 1725-1730.
23. Nelson,P.W. et al. (2000) A model of HIV-1 pathogenesis that includes an intracellular delay. Math. Biosci., 163, 201-215.
24. Nowak,M.A. and May,R.M. (2000) Virus Dynamics: Mathematical Principles of Immunology and Virology. Oxford University Press, Oxford, UK.
25. Perelson,A.S. and Nelson,P.W. (1999) Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev., 41, 3-44.
26. Phillips,A.N. et al. (2001) Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS, 15, 2211-2220.
27. Quinlan,J.R. (1992) Learning with continuous classes. In 5th Australian Joint Conference on Artificial Intelligence, World Scientific, Singapore, pp. 343-348.
28. Ribeiro,R.M. and Bonhoeffer,S. (1999) A stochastic model for primary HIV infection: Optimal timing of therapy. AIDS, 13, 351-357.
29. Ribeiro,R.M. and Bonhoeffer,S. (2000) Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl Acad. Sci. USA, 97, 7681-7686.
30. Riddler,S.A. et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med., 358, 2095-2106.
31. Shafer,R.W. et al. (1995) Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J. Infect. Dis., 172, 70-78.
32. Tan,W.Y. (1995) A stochastic model for drug resistance in AIDS chemotherapy and the HIV incubation distribution. Stat. Probab. Lett. 25, 289-299.
33. Verhulst,P.-F. (1845) Recherches mathematiques sur la loi d'accroissement de la population. Nouv mem de l'Academie Royale des Sci et Belles-Lettres de Bruxelles, 18, 1-41.
34. Volterra,V. (1931) Variations and fluctuations of the number of individuals in animal species living together. In Animal Ecology. McGraw-Hill, New York, USA.
35. Wu,H. et al. (1999) Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: Relationships to host factors, cellular restoration and virological endpoints. J. Infect. Dis., 179, 799-807.
36. Fu,Y.-X. (2001) Estimating mutation rate and generation time from longitudinal samples of DNA sequences. Mol. Biol. Evol., 18, 620-626.
37. Zaccarelli,M. et al. (2005) Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of hiv-infected patients. AIDS, 19, 1081-1089.